Gene:
CCND3
cyclin D3

PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

Overview

Alternate Names:  None
Alternate Symbols:  None
PharmGKB Accession Id: PA26152

Details

Cytogenetic Location: chr6 : p21.1 - p21.1
GP mRNA Boundary: chr6 : 41902671 - 42016610
GP Gene Boundary: chr6 : 41899671 - 42026610
Strand: minus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.
No related genes are available

Curated Information ?

Evidence Disease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Lipodystrophy

Publications related to CCND3: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Site-dependent differences in both prelamin A and adipogenic genes in subcutaneous adipose tissue of patients with type 2 familial partial lipodystrophy. Journal of medical genetics. 2009. Ara├║jo-Vilar D, et al. PubMed

LinkOuts

NCBI Gene:
896
OMIM:
123834
UCSC Genome Browser:
NM_001760
RefSeq RNA:
NM_001136017
NM_001136125
NM_001136126
NM_001760
RefSeq Protein:
NP_001129489
NP_001129597
NP_001129598
NP_001751
RefSeq DNA:
NT_007592
UniProtKB:
B3KQ22_HUMAN (B3KQ22)
CCND3_HUMAN (P30281)
Ensembl:
ENSG00000112576
GenAtlas:
CCND3
GeneCard:
CCND3
MutDB:
CCND3
ALFRED:
LO193859J
HuGE:
CCND3
Comparative Toxicogenomics Database:
896
ModBase:
P30281
HumanCyc Gene:
HS03590
HGNC:
1585

Common Searches